Extended Data Fig. 5: Phenotype of anti-Her2 CAR T cells isolated from E0771-Her2 expressing tumors.
From: FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
E0771-Her2 tumor bearing mice were treated with anti-Her2 CAR T cells and tumors analyzed by flow cytometry at day 9 post treatment. a, Proportion of CD8+ b, or CD8+Tcf1+ CAR T cells expressing Ki67. Data presented as mean ± SEM n = 10 mice per group combined from 2 experiments. c, Expression of PD-1, TIM-3 and Tox in CD8+ CAR T cells modified with the indicated transcription factor. Data obtained from concatenated samples of n = 5 mice from a representative experiment of n = 2. d, E0771-Her2 tumor-bearing mice were treated with CAR T cells and with a total of 4 doses of 200 μg of anti-PD-1 or 2A3 on days 0, 3, 7 and 11 post-treatments. Data presented as mean ± SEM of indicated number of mice. Statistics determined by Two-way ANOVA (*p < 0.05, **p < 0.01, ****p < 0.0001). e, Frequency of CD8+ and CD4+ T cells within the NGFR+ (CAR+ subset). Data represented as the mean ± SEM of n = 12 (control and id3), n = 8 (Tcf7), n = 11 (Foxo1-Ada) mice combined from two independent experiments. Source data are provided in the Source Data file.
